Molecular, clinical, and therapeutic determinants of outcome in <i>NPM1</i>-mutated AMLJad Othman, Richard Dillon, Elli Papaemmanuil et al.|Blood|2024Cited by 78
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trialsNicola Potter, Richard Dillon, Jelena Jovanović et al.|The Lancet Haematology|2025Cited by 9